ALTO NEUROSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.81 USD | +0.34% |
|
-1.25% | 0.00% |
| May. 21 | Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer | CI |
| May. 14 | Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 317.4 | - | - |
| Enterprise Value (EV) 1 | -32.9 | 40.8 | 317.4 |
| P/E ratio | -4.17 x | -3.89 x | -2.5 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | - | - | - |
| EV / FCF | 0.59 x | -0.55 x | -3.49 x |
| FCF Yield | 170% | -181% | -28.7% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 26,876 | - | - |
| Reference price 2 | 11.81 | 11.81 | 11.81 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -37.81 | -64.95 | -87.02 | -90.94 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -36.3 | -58.5 | -83.61 | -90.01 |
| Net income 1 | -27.71 | -36.3 | -61.3 | -83.33 | -89.71 |
| Net margin | - | - | - | - | - |
| EPS 2 | -8.051 | -9.730 | -2.833 | -3.038 | -4.720 |
| Free Cash Flow 1 | - | - | -56 | -74 | -91 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 11/22/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -11.76 | -14.39 | -15.9 | -17.25 | -17.45 | -22.1 | -23 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -11.22 | -13.42 | -13.6 | -14.7 | -16.7 | -19.3 | -19.8 |
| Net income 1 | -11.22 | -13.42 | -14.93 | -15.93 | -16.77 | -19.3 | -19.8 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -6.700 | -0.7600 | -0.6325 | -0.6675 | -0.6350 | -0.6900 | -0.7300 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/21/24 | 5/14/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 350 | 277 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -56 | -74 | -91 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 0.6 | 0.6 | 1 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 11/22/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.81
USD
Average target price
33.69
USD
Spread / Average Target
+185.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 317M | |
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- ANRO Stock
- Financials Alto Neuroscience, Inc.
